Medscape
SAN DIEGO — Boston Pharmaceuticals’ once-monthly efimosfermin alfa (formerly BOS-580) prescribed for metabolic dysfunction–associated steatohepatitis (MASH) with F2 and F3 fibrosis significantly improved MASH resolution and fibrosis after 24 weeks, according to results of a phase 2 trial presented at Digestive Disease Week (DDW) 2025. An analogue of the fibroblast growth factor 21 (FGF21) protein…
Read More
Efimosfermin Leads to Significant MASH Improvement
Randy Badon
12:20
SAN DIEGO — Boston Pharmaceuticals’ once-monthly efimosfermin alfa (formerly BOS-580) prescribed for metabolic dysfunction–associated steatohepatitis (MASH) with F2 and F3 fibrosis significantly improved MASH resolution and fibrosis after 24 weeks, according to results of a phase 2 trial presented at Digestive Disease Week (DDW) 2025. An analogue of the fibroblast growth factor 21 (FGF21) protein…
